CARACAS, VENEZUELA - April 7, 2026 (NEWMEDIAWIRE) - Catalyst Crew Technologies Corp. (OTC: CCTC) (the “Company”), a digital health and artificial intelligence technology company developing telehealth infrastructure and healthcare analytics platforms for emerging markets, today announced the development of PulmoAI, an artificial intelligence-enabled module designed to support the detection and predictive analysis of pulmonary diseases.
PulmoAI is intended to assist healthcare providers in analyzing respiratory health data and identifying potential clinical risks through artificial intelligence-driven analytics. Its proposed capabilities include automated interpretation of thoracic imaging, detection of pulmonary abnormalities, and predictive modeling of disease progression.
The platform is being developed to integrate multiple data inputs, including computed tomography (CT) scans, chest X-rays, pulmonary function tests, and inflammatory biomarkers, in order to generate structured outputs intended to support clinical review and care coordination.
PulmoAI forms part of the Company’s broader artificial intelligence healthcare platform and is expected to function as a specialized module within Catalyst Crew’s digital health ecosystem. Management believes that modular AI systems, such as PulmoAI, may support scalable deployment across telehealth services, remote diagnostics, and technology-enabled healthcare delivery environments.
The Company intends to integrate PulmoAI across its existing and planned healthcare infrastructure initiatives, including its healthcare services coordination platform. As development progresses, PulmoAI is expected to support early detection capabilities and data-driven insights across multiple points of care.
Catalyst Crew Technologies intends to prioritize market development in Latin America, where the Company believes artificial intelligence-enabled healthcare technologies may help expand access to respiratory diagnostics, support earlier identification of pulmonary conditions, and improve healthcare system efficiency.\
Dr. Kevin Rodan Levy, Chief Executive Officer of Catalyst Crew Technologies Corp., stated: “Artificial intelligence has the potential to enhance how healthcare providers detect and monitor pulmonary conditions, particularly in environments where access to specialized diagnostics may be limited. PulmoAI reflects our commitment to building scalable, technology-driven solutions to support healthcare delivery.”
The Company intends to continue developing and refining PulmoAI and its broader healthcare technology platform while evaluating opportunities for pilot programs, strategic partnerships, and phased market deployment.
For more information, please visit https://catalystcrewai.com or review the Company’s filings with the U.S. Securities and Exchange Commission at www.sec.gov.
About Catalyst Crew Technologies Corp.
Catalyst Crew Technologies Corp. is an artificial intelligence-driven healthcare technology company focused on developing scalable digital health solutions for emerging markets, with an initial emphasis on Latin America. The Company is actively executing its strategic transition into AI-enabled healthcare and pursuing opportunities across telehealth infrastructure, remote patient monitoring, healthcare data analytics, and integrated digital care platforms designed to improve access, efficiency, and care coordination.
Through technology development initiatives, strategic partnerships, and targeted acquisitions, CCTC is building an integrated healthcare technology platform positioned to address the growing demand for modernized healthcare delivery systems across emerging markets.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include, but are not limited to, statements regarding the Company’s business strategy, leadership initiatives, strategic transactions, operational execution, regulatory matters, and future operations.
Forward-looking statements are based on current expectations and assumptions that involve risks and uncertainties. Actual results may differ materially from those expressed or implied due to various factors, including but not limited to the Company’s ability to successfully implement its business plan, secure financing, complete acquisitions, comply with regulatory requirements, and general market and economic conditions.
The Company undertakes no obligation to update any forward-looking statements except as required by applicable law.
Disclaimer
This press release is provided for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company.
The Company is a development-stage enterprise and has not generated revenues from its newly announced business direction. There can be no assurance that the Company will successfully implement its business plan, complete acquisitions, secure financing, obtain regulatory approvals, or generate revenues.
Any investment decision should be made solely on the basis of information contained in the Company’s filings with the U.S. Securities and Exchange Commission and other publicly available documents. The Company’s securities involve a high degree of risk. Prospective investors are urged to carefully review all risk factors and disclosures contained in the Company’s SEC filings before making any investment decision.
No representation or warranty, express or implied, is made as to the accuracy or completeness of the information contained herein.
Investor Relations Contact
+1 (787) 476-2350
ir@catalystcrew.ai
View the original release on www.newmediawire.com
